Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG)
Winfred C. Wang(St. Jude Children's Research Hospital), Russell E. Ware(St. Jude Children's Research Hospital), Scott T. Miller(SUNY Downstate Health Sciences University), Rathi V. Iyer(University of Mississippi Medical Center), James F. Casella(Johns Hopkins Medicine), Caterina P. Minniti(Children's National), Sohail Rana(Howard University), Courtney D. Thornburg(Duke Medical Center), Zora R. Rogers(The University of Texas Southwestern Medical Center), Ram Kalpatthi(Medical University of South Carolina), Julio C. Barredo(University of Miami), R. Clark Brown(Emory University), Sharada A. Sarnaik(Children's Hospital of Michigan), Thomas H. Howard(University of Alabama at Birmingham), Lynn Wynn(St. Jude Children's Research Hospital), Abdullah Kutlar(Augusta University), F. Daniel Armstrong(University of Miami), Beatrice Files(Emory University), Jonathan C. Goldsmith(National Heart Lung and Blood Institute), Myron A. Waclawiw(National Heart Lung and Blood Institute), Xiangke Huang(Clinical Trials and Surveys Corporation), Bruce Thompson(Clinical Trials and Surveys Corporation)
Cited by 786
Abstract
Related Papers
Prediction of Adverse Outcomes in Children with Sickle Cell Disease
Scott T. Miller, Lynn A. Sleeper, Charles H. Pegelow et al.|New England Journal of Medicine|2000|513
The risks and benefits of long‐term use of hydroxyurea in sickle cell anemia: A 17.5 year follow‐up
Martin H. Steinberg, William F. McCarthy, Oswaldo Castro et al.|American Journal of Hematology|2010|480